AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04046978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mos3.1 33 ug, Mos3.2 33 ug and Mos3.3 33 ug
Description: Intramuscular injection of synthetic viral immunogens Mos3.1, Mos3.2 and Mos3.3
Study NCT03405519 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radiotherapy planning using both CT and MRI scans
Description: Patients' radiotherapy will be planned using CT and MRI scans in order to establish the best methodology for planning of radiotherapy for nodal disease
Study NCT03936647 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical clipping, simple coiling, high-porosity stenting with/ without coiling, intra-arterial flow diversion with/ without coiling
Description: Treatment may include the most appropriate amongst surgical clipping, simple coiling, high-porosity stenting with or without coiling, and intra-arterial flow diversion with or without coiling, which will be predetermined by the treating physician prior to randomization.
Study NCT03936647 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WEB embolization device
Description: WEB embolization device
Study NCT02643342 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthokeratology
Study NCT02643342 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Orthokeratology
Study NCT04311931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Dance Program
Description: All Creative Dance sessions comprised five phases: 1) opening ritual (5 min), in which participants will be welcomed and will be informed about the objectives and structure of the session; 2) warm-up (15 min), in which body muscle groups will be activated through the introduction of basics elements of movement; 3) main phase (30 min), will be proposed individual, pair and group activities, in order to achieve the objectives described above. This phase will end with a choreography composition; 4) cool-down (5 min) with stretching and physiological parameters normalization; and 5) ending ritual (5 min), in which the participants will be invented to share their sessions' experience and they will fill a sheet with attendance, exercise intensity perception (Borg Scale) and satisfaction's (Caregiver Treatment Satisfaction questionnaire).
Study NCT00077649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin [Copegus]
Description: 600mg po bid for 48 weeks
Study NCT00077649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: 600mg po bid for 48 weeks
Study NCT00077649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: 800mg po bid for 48 weeks
Study NCT00077649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]
Description: 180 micrograms sc weekly for 48 weeks
Study NCT00077649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]
Description: 180 micrograms sc weekly for 48 weeks
Study NCT00077649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]
Description: 270 micrograms sc weekly for 48 weeks
Study NCT02291588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 811
Description: A single dose of AMG 811 or placebo will be adminstered.
Study NCT02291588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: contains no active drug
Study NCT01174212 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic Antibiotics
Description: Preoperative Antibiotics
Study NCT01174212 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control Antibiotics
Description: Antibiotics will be held until intraoperative cultures have been obtained.
Study NCT00428870 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic acromioplasty or arthroscopy alone (sham) or conservative treatment (rehabilitation)
Study NCT00428870 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic acromioplasty or arthroscopy alone (sham) or conservative treatment (rehabilitation)
Study NCT03463720 — intervention group
Intervention type: OTHER
Intervention: Infected
Description: Extremity wound, infected
Study NCT03463720 — intervention group
Intervention type: OTHER
Intervention: Not infected
Description: Extremity wounds, non-infected
Study NCT02760420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Oral amoxicillin dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
Study NCT02760420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
Study NCT00394173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNK333
Description: DNK333 25mg b.i.d. given orally for 4 weeks
Study NCT00394173 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT03077646 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Be SMART
Description: An educational campaign that is non-political reviewing gun safety measures for preventing firearm injuries in children. There is both a video and written materials reviewing the information. The acronym SMART stands for: Secure all guns in your home, Model responsible behavior, Ask about unsecured guns in other homes, Recognize the risks of teen suicide, Tell your peers to be SMART
Study NCT03077646 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control: TSE
Description: A video called Kids and Smoke Don't Mix and handouts on tobacco smoke exposure (TSE) developed by the New York state quit-line.
Study NCT03077646 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Be SMART + MD review
Description: An educational campaign that is non-political reviewing gun safety measures for preventing firearm injuries in children. There is both a video and written materials reviewing the information. The acronym SMART stands for: Secure all guns in your home, Model responsible behavior, Ask about unsecured guns in other homes, Recognize the risks of teen suicide, Tell your peers to be SMART.~After being presented to parents/guardians via video and handouts, this information will be reviewed in person with a Physician.
Study NCT00553319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group
Study NCT00553319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adderall-XR
Description: Adderall-XR 60mg/day
Study NCT00553319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adderall-XR
Description: Adderall-XR 80mg/day
Study NCT04651153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB7853
Description: Subjects will receive UCB7853 at pre-specified time-points.
Study NCT04651153 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive Placebo at pre-specified time-points.
Study NCT02727452 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Skin-to-skin contact
Study NCT02727452 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Skin-to-skin contact
Study NCT00428870 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Arthroscopic acromioplasty or arthroscopy alone (sham) or conservative treatment (rehabilitation)
Study NCT00938691 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intradermal Suture
Study NCT00938691 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intradermal Suture
Study NCT01862653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular Acupuncture
Description: Subjects receiving the auricular acupuncture intervention will be treated in a quiet private room sitting in a comfortable chair. The external ear cartilage of both ears will be cleaned with isopropyl alcohol swabs. A clean insertion technique will be used with stainless steel SEIRIN D type acupuncture needles (0.20mm diameter, 15mm length) on each of the identified acupuncture points (Shen men, Point zero, brain, thalamus, Pineal, Master cerebral, Insomnia 1, Kidney, Heart, Insomnia 2, Occiput, Forehead) to bilateral ears for a total of 30 minutes. Acupuncture will be administered by a board certified Psychiatrist with supplemental privileges to perform acupuncture.
Study NCT02175914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin
Description: Oral Treatment with Erythromycin 500mg, twice daily, for 12 weeks
Study NCT03028935 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo instructor-led exercise program
Study NCT03028935 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: Undergo instructor-led nutritional education program
Study NCT03821116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk
Description: Swedish milk from cow.
Study NCT03821116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soured milk (filmjölk)
Description: Swedish soured milk (from cow milk).
Study NCT02727452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact
Study NCT02004457 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABBT
Study NCT02004457 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: TAU
Study NCT02424682 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention administered in this study
Study NCT03979924 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Trismus rehabilitation
Description: The patient will be followed-up by a physiotherapist during all the whole radiotherapy treatment, with short 15-min sessions, twice a week. He/she will be trained to perform regularly and by him/herself the preventive/rehabilitation exercises than the patient will do twice a day until the end of the radiotherapy treatment. The patient will then continue, in an autonomous manner, with his/her rehabilitation.~In case of trismus occurrence, the physiotherapist will advise the patient to add a passive tool to the active exercises (Jaw Trainer, Therabite, tongue depressors,...) in order to strengthen the stretching.
Study NCT02142569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CRYR + TRF
Description: CRYR 1200mg/day, including 6 mg mevinolin as Monacolin K (2 capsules) + TRF 300mg/day including 60 mg tocotrienols (2 capsules) per day for 12 weeks.
Study NCT05166031 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bOPV and nOPV2
Description: Approximately 265 subjects will receive 2 doses of bOPV, nOPV2 or bOPV + nOPV2 per arm separated by 28 days between doses.
Study NCT05166031 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bOPV and nOPV2
Description: Approximately 265 subjects will receive 2 doses of bOPV, nOPV2 or bOPV + nOPV2 per arm separated by 28 days between doses.
Study NCT00508118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicardipine
Description: on bypass
Study NCT00508118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: on bypass
Study NCT01834040 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intralesional/ Intravenous of Autologous Stem cells.
Description: Intralesional/ Intravenous of Autologous MNCs per dose
Study NCT03851315 — intervention group
Intervention type: DEVICE
Intervention: permanent left bundle branch area pacing
Description: Implant the pacing lead in the left bundle branch area instead of traditional RV pacing site(septal or apical). Successful LBBAP was defined as the paced QRS morphology of right bundle branch block pattern in lead V1 and QRS duration (QRSd) less than 130ms.
Study NCT01845129 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: atDCS
Description: atDCS will be delivered with a constant current of 1 mA during simultaneous resting-state (RS) and task-related (picture naming) functional magnetic resonance imaging (fMRI). The current will be turned on prior to the RS-fMRI scan and continues for 20 minutes.
Study NCT01845129 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: atDCS
Description: atDCS will be delivered with a constant current of 1 mA during simultaneous resting-state (RS) and task-related (picture naming) functional magnetic resonance imaging (fMRI). The current will be turned on prior to the RS-fMRI scan and continues for 20 minutes.
Study NCT01845129 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham tDCS
Description: During sham the current will be increeased and decreased in a ramp-like fashion (10 sec)
Study NCT01845129 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: During sham the current will be increeased and decreased in a ramp-like fashion (10 sec)
Study NCT03721406 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ropivacaine
Description: ropivacaine administerd via thoracic paraveretebral catheter
Study NCT01279421 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Network HIV Testing
Description: Crack users will be recruited for HIV testing and receive 3 coupons to recruit other crack users for HIV testing.
Study NCT01279421 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Network Intervention
Description: Peer leaders will recruit small networks of crack users and facilitate a three-day prevention intervention.
Study NCT01513460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237 50µg once daily
Description: NVA237 50 μg o.d., delivered via single-dose dry-powder inhaler (SDDPI)
Study NCT01513460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium 18µg once daily
Description: Tiotropium 18 μg o.d. delivered via a proprietary inhalation device
Study NCT01513460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Flu/Sal
Description: Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device
Study NCT01513460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flu/Sal
Description: Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device
Study NCT01513460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flu/Sal
Description: Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device
Study NCT01513460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NVA237 placebo + Tiotropium placebo.
Description: Tiotropium 18 μg o.d. delivered via a proprietary inhalation device
Study NCT01513460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237 placebo + Tiotropium placebo.
Description: Tiotropium 18 μg o.d. delivered via a proprietary inhalation device
Study NCT01513460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVA237 placebo + Tiotropium placebo.
Description: Tiotropium 18 μg o.d. delivered via a proprietary inhalation device
Study NCT00381810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be supplied as a liquid for intravenous infusion.
Study NCT00381810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Study NCT00381810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Study NCT00381810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Study NCT00720291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Patients who are randomly assigned to receive Metronidazole will receive 500 mg po bid Metronidazole for 7 days
Study NCT04077931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: Walking on treadmill with fixed 0% grade inclination
Study NCT03537196 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sofosbuvir 400 mg and Daclatasvir 60 mg
Description: All patients will receive sofosbuvir 400-mg and daclatasvir 60-mg (1 tablet each per day) during 12 weeks.
Study NCT03537196 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sofosbuvir 400 mg and Daclatasvir 90 mg
Description: For HIV/HCV co-infected patients receiving efavirenz or nevirapine, daclatasvir dose will be increased to 90-mg per day.
Study NCT03537196 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ribavirin
Description: In case of cirrhosis:~* Ribavirin will be added to sofosbuvir/daclatasvir during the 12 weeks of treatment. The dose will be adapted to the patient weight although the vast majority of patients (weight \< 75 kg) will receive 500 mg x 2/day.~* In case of ribavirin contra-indication or side effects leading to ribavirin discontinuation, sofosbuvir/daclatasvir will be used 24 weeks.
Study NCT00720291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients who are randomly assigned to receive a placebo will receive a placebo pill po bid for 7 days.
Study NCT01192139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saxagliptin
Description: Tablets, Oral, 5 mg, once daily, Single dose
Study NCT01192139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin XR
Description: Tablets, Oral, 500 mg. once daily, Single dose
Study NCT01192139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saxagliptin + metformin XR (FDC tablet)
Description: Tablet, Oral, (saxagliptin 5 mg)(metformin XR 500 mg), once daily, Single dose
Study NCT02142569 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tocotrienol-enriched Fraction of Palm Oil (TRF)
Description: TRF 300mg/day, including 60 mg tocotrienols (2 capsules) + placebo (2 capsules) per day for 12 weeks.
Study NCT00131404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taranabant
Description: taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule once daily. 52 week treatment period.
Study NCT03579004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is used in two cycles of neoadjuvant chemotherapy and concomitant chemoradiotherapy
Study NCT03579004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is used in two cycles of neoadjuvant chemotherapy and concomitant chemoradiotherapy
Study NCT03579004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil is used in two cycles of neoadjuvant chemotherapy
Study NCT03579004 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chemoradiotherapy
Description: Distant 3D radiotherapy, single dose 2 Gray (Gy), total dose 44Gy.
Study NCT03579004 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ivor Lewis esophagogastrectomy
Description: Open Ivor Lewis esophagogastrectomy
Study NCT01305616 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification with yellow-tinted intraocular lens
Description: Phacoemulsification is a kind of cataract surgery using ultrasound machine. Yellow-tinted intraocular lens are a sort of lens with the ability to filter blue and ultraviolet spectrum of light (380-500 nanometer)
Study NCT01305616 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Phacoemulsification with yellow-tinted intraocular lens
Description: Phacoemulsification is a kind of cataract surgery using ultrasound machine. Yellow-tinted intraocular lens are a sort of lens with the ability to filter blue and ultraviolet spectrum of light.
Study NCT03048981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: Blood samples before and after 10 day intake of maximum dose fish oil
Study NCT05043896 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Li-ESWT
Description: Li-ESWT twice weekly for 4 weeks
Study NCT05043896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 2.5Mg Tab
Description: tadalafil 2.5mg once daily
Study NCT05043896 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Tadalafil 2.5Mg Tab
Description: tadalafil 2.5mg once daily
Study NCT03977376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guide of hosting
Description: Guide of hosting with information about hospitalization to decrease anxiety
Study NCT00219531 — intervention group
Intervention type: BEHAVIORAL
Intervention: perception of rectal balloon distention
Description: functional Magnetic Resonance Imaging (fMRI) study with measurement of brain MRI response to rectal balloon distention.
Study NCT00003824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cephalexin
Description: 500 mg oral bid for 3 days starting the night before resection
Study NCT03537196 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sofosbuvir and Daclatasvir for 24 weeks
Description: In case of cirrhose and of ribavirin contra-indication or side effects leading to ribavirin discontinuation, sofosbuvir/daclatasvir will be used 24 weeks.
Study NCT05113914 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardio-pulmonary exercise test
Description: An incremental running test was conducted on the treadmill. Initially, the exercise protocol included standing still for 3 min and walking for 3 min at a constant speed of 4 km/h. After this introductory part, the speed was increased to 8 km/h and then every 3 min by 2 km/h until the volitional exhaustion was reached. During all procedure oxygen consumption was measured with the use of a portable breath-by-breath ergospirometer.
Study NCT04870918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-care intervention
Description: Health education will be carried out by the nurse.